SG11202107659SA - New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine - Google Patents

New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine

Info

Publication number
SG11202107659SA
SG11202107659SA SG11202107659SA SG11202107659SA SG11202107659SA SG 11202107659S A SG11202107659S A SG 11202107659SA SG 11202107659S A SG11202107659S A SG 11202107659SA SG 11202107659S A SG11202107659S A SG 11202107659SA SG 11202107659S A SG11202107659S A SG 11202107659SA
Authority
SG
Singapore
Prior art keywords
treatment
diseases characterized
new recombinant
diamine oxidase
excess histamine
Prior art date
Application number
SG11202107659SA
Other languages
English (en)
Inventor
Thomas Böhm
Bernd Jilma
Nicole Borth
Elisabeth Gludovacz
Original Assignee
Univ Wien Med
Univ Wien Bodenkultur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wien Med, Univ Wien Bodenkultur filed Critical Univ Wien Med
Publication of SG11202107659SA publication Critical patent/SG11202107659SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0022—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C12Y104/03022—Diamine oxidase (1.4.3.22)
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/20—Sequence assembly
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G16B35/10—Design of libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Library & Information Science (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
SG11202107659SA 2019-02-19 2020-02-18 New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine SG11202107659SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19157932 2019-02-19
PCT/EP2020/054197 WO2020169577A1 (en) 2019-02-19 2020-02-18 New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine

Publications (1)

Publication Number Publication Date
SG11202107659SA true SG11202107659SA (en) 2021-09-29

Family

ID=65493995

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202107659SA SG11202107659SA (en) 2019-02-19 2020-02-18 New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine

Country Status (14)

Country Link
US (1) US20220145269A1 (enExample)
EP (1) EP3927817B1 (enExample)
JP (1) JP7792252B2 (enExample)
KR (1) KR20210132650A (enExample)
CN (1) CN113785052B (enExample)
AU (1) AU2020225319B2 (enExample)
BR (1) BR112021015865A2 (enExample)
CA (1) CA3130751A1 (enExample)
EA (1) EA202192305A1 (enExample)
ES (1) ES3041133T3 (enExample)
IL (1) IL285452B2 (enExample)
MX (1) MX2021010050A (enExample)
SG (1) SG11202107659SA (enExample)
WO (1) WO2020169577A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10947552B1 (en) 2020-09-30 2021-03-16 Alpine Roads, Inc. Recombinant fusion proteins for producing milk proteins in plants
WO2022072718A1 (en) 2020-09-30 2022-04-07 Nobell Foods, Inc. Recombinant milk proteins and food compositions comprising the same
US10894812B1 (en) 2020-09-30 2021-01-19 Alpine Roads, Inc. Recombinant milk proteins
EP4496488A4 (en) * 2022-03-21 2025-11-26 Cedars Sinai Medical Center METHODS AND COMPOSITIONS FOR THE SUPPRESSION OF BIOGENIC AMINES PRODUCED BY THE INTESTINAL MICROBIOME
IL317379A (en) * 2022-06-03 2025-02-01 Oyster Point Pharma Inc AAV vector encoding diamine oxidase and its uses
EP4782002A1 (en) * 2025-01-27 2026-07-29 DR Healthcare S.L.U. Diamine oxidase (dao) for use in the treatment of infertility
CN121975758B (zh) * 2026-04-02 2026-07-14 华中科技大学同济医学院附属同济医院 组胺氧化酶蛋白及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK402785D0 (da) * 1985-09-03 1985-09-03 Syn Tek Ab Fremgangsmaade til fremstilling af et enzym
US6075007A (en) * 1997-07-17 2000-06-13 Regeneron Pharmaceuticals, Inc. Modified noggin polypeptide and compositions
IT1317067B1 (it) * 2000-11-29 2003-05-26 Univ Roma Istaminasi di origine vegetale nel trattamento dello shock allergico esettico e nell'asma allergico.
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
CA2536016C (en) * 2002-08-16 2017-01-10 Paul L. Deangelis Targeted glycosaminoglycan polymers by polymer grafting and methods of making and using same
US20050255114A1 (en) * 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
AT502098B8 (de) * 2004-07-07 2007-06-15 Albert Dr Missbichler Diaminooxidase-hältige zusammensetzung
CA2660286A1 (en) * 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
WO2012028891A1 (en) * 2010-09-02 2012-03-08 Debreceni Egyetem Perorally applicable preparation containing histaminase of vegetable origin, resistant to pepsin and trypsin and a process for producing it
JP2014518632A (ja) * 2011-06-01 2014-08-07 モアハウス スクール オブ メディスン ケモカイン−免疫グロブリン融合ポリペプチド、組成物、その作製および使用の方法
AU2015332533B2 (en) * 2014-10-14 2018-08-30 Halozyme, Inc. Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same
WO2023122254A2 (en) * 2021-12-22 2023-06-29 The Board Of Trustees Of The Leland Stanford Junior University Methods to elicit desire to mate and mating behavior

Also Published As

Publication number Publication date
ES3041133T3 (en) 2025-11-07
EP3927817C0 (en) 2025-08-20
AU2020225319B2 (en) 2025-05-29
KR20210132650A (ko) 2021-11-04
US20220145269A1 (en) 2022-05-12
BR112021015865A2 (pt) 2021-10-05
WO2020169577A1 (en) 2020-08-27
CA3130751A1 (en) 2020-08-27
EP3927817B1 (en) 2025-08-20
CN113785052A (zh) 2021-12-10
IL285452B2 (en) 2025-07-01
CN113785052B (zh) 2024-06-28
IL285452A (en) 2021-09-30
MX2021010050A (es) 2021-09-21
JP2022520862A (ja) 2022-04-01
EP3927817A1 (en) 2021-12-29
AU2020225319A1 (en) 2021-10-14
IL285452B1 (en) 2025-03-01
JP7792252B2 (ja) 2025-12-25
EA202192305A1 (ru) 2021-12-08

Similar Documents

Publication Publication Date Title
IL288214A (en) Quinazolin-4-one derivatives are useful for the treatment of braf-related diseases and disorders
IL278178A (en) Use of pilocarpine hydrochloride to treat eye disorder
IL285452A (en) New recombinant diamine oxidase and its use for the treatment of diseases characterized by excess histamine
IL291735A (en) Heteroarylbiphenylamines for the treatment of pd-l1 diseases
IL289405A (en) Personalized treatment of eye diseases
IL287280A (en) Compounds and methods for the treatment of ocular disorders
EP4009948A4 (en) USE OF TGF-ALPHA POLYPEPTIDES OR ANTI-TGF-ALPHA ANTIBODIES FOR TREATING DISEASES AND DISORDERS
HUE067909T2 (hu) Pirimidin JAK-inhibitorok bõrbetegségek kezelésére
SG11202011010YA (en) 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
ZA202206743B (en) Therapy for the treatment of cancer
SG11202011018PA (en) 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
IL286000A (en) Asketamine for the treatment of depression
IL292657A (en) Therapeutic history of interleukin-22
IL287264A (en) Compounds and methods for the treatment of ocular disorders
EP3744347A4 (en) COMPOSITION FOR USE IN THE TREATMENT OF SKIN DISEASES
ZA202106250B (en) Therapeutic uses of dulaglutide
EP4034240A4 (en) TREATMENT OF TAUOPATHIES
GB201918404D0 (en) Compounds and their use for the treatment of aplha1-antitrypsin deficiency
SG11202010034WA (en) TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRß ANTIBODY
GB2574747B (en) Use of lambda interferons in the treatment of obesity-related disorders and related diseases
PL3937948T3 (pl) Fitoekdyzony i ich pochodne do ich zastosowania w leczeniu chorób nerwowo-mięśniowych
SI3897655T1 (sl) 3beta-(benziloksi)-17alfa-metil-pregn-5-en-20-on za uporabo pri zdravljenju kognitivnih motenj
GB2603379B (en) Avocatin B for the treatment of diseases and conditions
EP3661494B8 (en) Use of tasimelteon for the treatment of affective disorders in majority black african patients
HK40076274A (en) Use of tgf-alpha polypeptide or anti-tgf-alpha antibodies for the treatment of diseases and disorders